findmyKOL
Clinical trialNCT03407703UnknownObservational

Hepatitis C (HCV) Cure and Kidney Health

SponsorSan Francisco Veterans Affairs Medical CenterEnrollment50Hepatitis C
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to learn how 12 weeks of HCV treatment with elbasvir and grazoprevir (brand name Zepatier) impacts your kidney function.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • San Francisco Va Medical Center

    San Francisco, California, United States

    Recruiting
  • University of California, San Francisco

    San Francisco, California, United States

    Enrolling, by, invitation

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elbasvir
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
27 Mar 2018
Primary completion
31 Dec 2019
Completion
31 Dec 2019
Last update posted
18 Apr 2018
Registered enrollment
50
Registry id
NCT03407703
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.